FDA Policy and Goals Regarding the 483 Response - 2017

Website http://www.compliance4all.com/control/w_product/~product_id=501115LIVE?channel=ourglocal_Jun_2017_SE | Edit Freely

Category FDA Policy and Goals, FDA Form 483, Regulatory Affairs, FDA Compliance Webinars, global regulatory affairs, online Fda Webinars, pharmaceutical regulatory affairs, Online Fda Programs, 2017 Fda Webinars, latest 2017 webinars, USA webinars

Deadline: June 06, 2017 | Date: June 06, 2017

Venue/Country: Online, U.S.A

Updated: 2017-04-24 18:31:22 (GMT+9)

Call For Papers - CFP

FDA policy and goals regarding the 483 response are discussed. Examples of both good and poor responses are given. Warning Letters and responses are discussed and the implications of both a good and poor response to a possible Warning Letter are given.

Why you should attend:

Learn how to respond to FDA 483's and the best way to write the response. Learn the new policy from FDA regarding how and when to respond. Learn the best way to respond in case a Warning Letter is issued. Learn what is a satisfactory response to FDA and what is not.

Areas Covered in the Session:

How to respond to an FDA Form 483

Using the preferred format

The timing of the response

The wording and tone of the response

What to include as attachments

What to include in the response itself

Who Will Benefit:

Manager/Director QA

Manager/Director Regulatory Affairs

Speaker Profile:

John R. Godshalk currently works for the Biologics Consulting Group as a Senior Consultant. John served as a Senior Review Biochemical Engineer and Lead cGMP inspector in the Division of Manufacturing and Product Quality at CBER, FDA. He contributed to formulation of FDA policy.

Contact Detail:

Compliance4All DBA NetZealous,

Phone: +1-800-447-9407

Email: supportcompliance4All.com